Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).
SparkCures ID | 222 |
---|---|
Developed By | Cellectar Biosciences |
Generic Name | Iopofosine I-131 (CLR 131) |
Additional Names | I-131-CLR1404, CLR131, CLR-131, CLR 131, iopofosine |
Treatment Classifications |
|
Tags |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
September 09, 2020
The 40% ORR (6/15 patients) represents triple class refractory patients enrolled in Part A of Cellectar’s CLOVER-1 study and additional patients enrolled in Part B from March through May 2020. As a reminder, all patients being enrolled in Part B are required to be triple class refractory. The additional six patients were heavily pre-treated with an average of 9 prior multi-drug regimens. Three patients received a total administered dose of greater than 60 mCi and three received less than 60 mCi. Consistent with the data released in February 2020, patients receiving greater than 60 mCi exhibit strong responses. Patients continue to tolerate CLR 131 well, with the most common and almost exclusive treatment emergent adverse events being cytopenias and importantly, no unexpected adverse events have been reported.
May 14, 2019
September 27, 2019
SparkCures is working closely with Cellectar Biosciences to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners